1KCN

Structure of e109 Zeta Peptide, an Antagonist of the High-Affinity IgE Receptor

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D NOESY	2mM e109 peptide, pH 5.4, 0.1 mM NaN3, 0.1 mM DSS	92% H2O/8% D2O		5.4	ambient	288
2	DQF-COSY	2mM e109 peptide, pH 5.4, 0.1 mM NaN3, 0.1 mM DSS	92% H2O/8% D2O		5.4	ambient	288
3	2D TOCSY	2mM e109 peptide, pH 5.4, 0.1 mM NaN3, 0.1 mM DSS	92% H2O/8% D2O		5.4	ambient	288
4	2D COSY-35	2mM e109 peptide, pH 5.4, 0.1 mM NaN3, 0.1 mM DSS	100% D2O		5.4	ambient	288
5	2D NOESY	2mM e109 peptide, pH 5.4, 0.1 mM NaN3, 0.1 mM DSS	100% D2O		5.4	ambient	288
6	2D ROESY	2mM e109 peptide, pH 5.4, 0.1 mM NaN3, 0.1 mM DSS	92% H2O/8% D2O		5.4	ambient	288

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	DRX	500

NMR Refinement
Method	Details	Software
hybrid distance geometry/simulated annealing, then further refined by restrained molecular dynamics	The structures are based on a total of 101 NOE-derived distance restraints, 18 dihedral angle restraints, and 12 distant restraints from 6 hydrogen bonds.	XwinNMR

NMR Ensemble Information
Conformer Selection Criteria	structures with acceptable covalent geometry,structures with the least restraint violations
Conformers Calculated Total Number	50
Conformers Submitted Total Number	20
Representative Model	1 (closest to the average)

Additional NMR Experimental Information
Details	This structure was determined using standard 2D homonuclear techniques. 3JHNHA WERE OBTAINED BY FITTING LORENTZIAN LINES TO THE ANTIPHASE DOUBLETS OF HN-HA PEAKS IN A 2QF-COSY SPECTRUM PROCESSED TO HIGH DIGITAL RESOLUTION IN F2. 3JHAHB WERE EXTRACTED FROM A COSY-35 SPECTRUM ACQUIRED IN D2O

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	XwinNMR	2.1	Bruker, Inc.
2	data analysis	Felix	98.0	Molecular Simulations, Inc.
3	structure solution	DGII	98.0	Molecular Simulations, Inc.
4	refinement	Discover	98.0	Molecular Simulations, Inc.

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.